PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34952465-10	2022	In vivo study showed that lenalidomide inhibited pro-inflammatory cytokines TNF-alpha and IL-6 while enhanced anti-fibrotic cytokines IFN-gamma and IL-10 in bleomycin-induced inflammation model, and attenuated pulmonary fibrosis and collagen deposition in the following fibrosis stage.	Lenalidomide	26-38	interleukin 10	Homo sapiens	148-153	
29986852-10	2018	Change in CSF interleukin-10 at 1 month correlated with clinical response and response duration to lenalidomide.	Lenalidomide	99-111	interleukin 10	Homo sapiens	14-28	
32321757-5	2020	Pharmacological targeting of IKZF3 with the drug lenalidomide showed that IKZF3 is required for anti-CD3/CD28 mAb-mediated induction of IL-10 but is dispensable for ex vivo IL-10 expression.	Lenalidomide	49-61	interleukin 10	Homo sapiens	136-141	
32761232-4	2020	Both lenalidomide and pomalidomide dose-dependently inhibited interleukin-12 (IL-12) and TNF production and STAT4 expression, and enhanced IL-10 production in response to LPS.	Lenalidomide	5-17	interleukin 10	Homo sapiens	139-144	
31141702-3	2019	Lenalidomide did not affect the viability or expression of costimulatory molecules, but it potently suppressed the production of the key inflammatory cytokines IL-12 and IL-23, and enhanced the production of the anti-inflammatory cytokine IL-10 by CD1c+ DCs.	Lenalidomide	0-12	interleukin 10	Homo sapiens	239-244	
29379494-0	2017	The CXCR4-STAT3-IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide.	Lenalidomide	121-133	interleukin 10	Homo sapiens	16-21	
29379494-5	2017	Furthermore, experiments to assess the role of lenalidomide, an immunomodulatory agent with direct antitumor effect as well as pleiotropic activity on the immune system, showed that this agent prevents a CXCL12-induced increase in p-S727-STAT3 and the IL-10 response by CLL cells.	Lenalidomide	47-59	interleukin 10	Homo sapiens	252-257	
29379494-6	2017	Lenalidomide also suppressed IL-10-induced Y705-STAT3 phosphorylation in healthy T cells, thus reversing CLL-induced T-cell dysfunction.	Lenalidomide	0-12	interleukin 10	Homo sapiens	29-34	
29379494-8	2017	Lenalidomide appears to be able to reverse CLL-induced immunosuppression through including abrogation of the CXCL12-CXCR4-S727-STAT3-mediated IL-10 response by CLL cells and prevention of IL-10-induced phosphorylation of Y705-STAT3 in T cells.	Lenalidomide	0-12	interleukin 10	Homo sapiens	142-147	
29379494-8	2017	Lenalidomide appears to be able to reverse CLL-induced immunosuppression through including abrogation of the CXCL12-CXCR4-S727-STAT3-mediated IL-10 response by CLL cells and prevention of IL-10-induced phosphorylation of Y705-STAT3 in T cells.	Lenalidomide	0-12	interleukin 10	Homo sapiens	188-193	
25398834-8	2015	Gene expression signature, induced by lenalidomide in nurse-like cells, indicated a reduction of pivotal pro-survival signals for chronic lymphocytic leukemia, such as CCL2, IGF1, CXCL12, HGF1, and supported a modulation towards M1 phenotype with high IL2 and low IL10, IL8 and CD163.	Lenalidomide	38-50	interleukin 10	Homo sapiens	264-268	
24482747-4	2013	In particular, lenalidomide has been shown to stimulate the cytotoxic functions of T lymphocytes and natural killer cells, to limit the immunosuppressive impact of regulatory T cells, and to modulate the secretion of a wide range of cytokines, including tumor necrosis factor alpha, interferon gamma as well as interleukin (IL)-6, IL-10, and IL-12.	Lenalidomide	15-27	interleukin 10	Homo sapiens	331-336	
22733396-4	2013	We demonstrate that exposure to lenalidomide in the context of T-cell expansion with direct ligation of CD3/CD28 complex results in polarization toward a Th1 phenotype characterized by increased IFN-gamma, but not IL-10 expression.	Lenalidomide	32-44	interleukin 10	Homo sapiens	214-219	
21748755-6	2012	RESULTS: Treatment with lenalidomide was associated with global changes in immunoreactivity to a number of prostate-associated antigens, as well as with changes in circulating levels of the T(H) 2 cytokines IL-4, IL-5, IL-10, and IL-13.	Lenalidomide	24-36	interleukin 10	Homo sapiens	219-224